Cleveland Clinic, Cleveland, OH, USA.
University of Kentucky HealthCare, Lexington, KY, USA.
Int J Artif Organs. 2021 Dec;44(12):938-943. doi: 10.1177/03913988211016007. Epub 2021 May 13.
The objective of this study was to determine if propofol administration to veno-venous (VV) extracorporeal membrane oxygenation (ECMO) patients was associated with more incidents of oxygenator failure when compared to patients who did not receive propofol. This was a single center, retrospective cohort study. The primary outcome of the study is oxygenator exchanges per ECMO day in patients who received propofol versus those who did not receive propofol. Patients were 18 years or older on VV-ECMO support between January 1, 2015 and January 31, 2018. Patients were excluded if they required ECMO support for less than 48 h or greater than 21 days. There were five patients in the propofol arm that required oxygenator exchanges and seven patients in the control arm. The total number of oxygenator exchanges per ECMO day was not significantly different between groups ( = 0.50). When comparing those who required an oxygenator exchange and those who did not, there was no difference in the cumulative dose of propofol received per ECMO hour (0.64 mg/kg/h vs 0.96 mg/kg/h; = 0.16). Propofol use in patients on VV-ECMO does not appear to increase the number of oxygenator exchanges.
本研究旨在确定与未接受异丙酚的患者相比，向静脉-静脉（VV）体外膜肺氧合（ECMO）患者给予异丙酚是否与更多的氧合器故障事件相关。这是一项单中心回顾性队列研究。该研究的主要结局是接受异丙酚的患者与未接受异丙酚的患者在 ECMO 日期间的氧合器更换次数。患者在 2015 年 1 月 1 日至 2018 年 1 月 31 日期间在 VV-ECMO 支持下年龄为 18 岁或以上。如果患者接受 ECMO 支持的时间少于 48 小时或超过 21 天，则将其排除在外。在异丙酚组中有 5 名患者需要更换氧合器，对照组中有 7 名患者需要更换氧合器。每组 ECMO 日的氧合器更换总数没有显著差异（ = 0.50）。在比较需要更换氧合器的患者和不需要更换氧合器的患者时，每小时 ECMO 接受的异丙酚累积剂量没有差异（0.64 mg/kg/h 与 0.96 mg/kg/h； = 0.16）。VV-ECMO 患者使用异丙酚似乎不会增加氧合器更换次数。
